CO

Coloplast A/S (COLO-B)

HealthcareMedical Instruments & Supplies
406.20DKK
-1.02%
Magic Rank
#11
Earnings Yield
7.3%
Return on Capital
176.8%
Market Cap
94B

Performance vs S&P 500 (5Y)

COLO-B.CO
S&P 500

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Magic Formula Analysis

Enterprise Value95.7B
Market / Universe
dk
Denmark

"A company with high ROC and high EY is statistically more likely to outperform the market."

Key Indicators

P/E Ratio23.54
Dividend Yield5.7%
Debt to Equity0.10
Gross Margin26.3%